Literature DB >> 640576

Oral testosterone, a reappraisal.

P R Daggett, M J Wheeler, J D Nabarro.   

Abstract

A microparticulate form of free testosterone was given orally to 6 hypogonadal men. Plasma levels were followed after a 200-mg dose, and a double-peak effect was observed. This suggests that particles of different sizes were absorbed at different rates. The clinical and biochemical effects were observed over a 2-month period, on a dose of 200 mg twice daily, taken in place of the usual androgen replacement. The results indicate that absorption is not sufficiently reliable for routine use. The large doses required to achieve therapeutic levels, make oral administration of free testosterone impractical.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 640576     DOI: 10.1159/000178904

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  16 in total

1.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

2.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.

Authors:  Christin N Snyder; Richard V Clark; Ralph B Caricofe; Mark A Bush; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2010-04-08

3.  Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

Authors:  John K Amory; Mark A Bush; Hui Zhi; Ralph B Caricofe; Alvin M Matsumoto; Ronald S Swerdloff; Christina Wang; Richard V Clark
Journal:  J Urol       Date:  2010-12-18       Impact factor: 7.450

Review 4.  Intestinal lymphatic vasculature: structure, mechanisms and functions.

Authors:  Jeremiah Bernier-Latmani; Tatiana V Petrova
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-28       Impact factor: 46.802

5.  Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.

Authors:  M Y Roth; R E Dudley; L Hull; A Leung; P Christenson; C Wang; R Swerdloff; J K Amory
Journal:  Int J Androl       Date:  2010-10-24

Review 6.  Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.

Authors:  Alexander W Pastuszak; Marc Gittelman; James P Tursi; Jonathan S Jaffe; David Schofield; Martin M Miner
Journal:  Andrology       Date:  2021-10-08       Impact factor: 4.456

Review 7.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

8.  Bioavailability of oral testosterone in males.

Authors:  H Frey; A Aakvaag; D Saanum; J Falch
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

9.  Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone.

Authors:  U Täuber; K Schröder; B Düsterberg; H Matthes
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

10.  Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.

Authors:  Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad
Journal:  Biochem Pharmacol       Date:  2018-08-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.